Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
102.20    -1.00 (-0.97%)
Bid:
101.60
Ask:
102.20
Spread: 0.60 (0.591%)
Market Cap: £167.55m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Trading and refinancing update

19 Mar 2026 07:00

RNS Number : 2207X
Synthomer PLC
19 March 2026
 

Synthomer plcTrading and refinancing update

 

· 2025 performance reconfirmed with positive cash, robust earnings and improved margin performance

· 2026 started as expected; in line with prior year and with momentum building

· Focused on refinancing discussions and divestment programme, which are both progressing constructively

 

2025 results and current trading in 2026

 

Synthomer plc ("Synthomer" or the "Company") today announces that the year to 31 December 2025 audit process is well-advanced, with no change to the expectations indicated in the 29 January 2026 trading update of continuing revenue of c.£1.74bn and continuing EBITDA in the range of £135-138m.

 

Strong operational execution, together with expanded 'self-help' cost reduction programmes, enabled the Company to mitigate the impact of softer end-market demand since global tariff changes were announced and deliver resilient earnings and an increased EBITDA margin as well as positive Free Cash Flow in 2025.

 

Synthomer's covenant net debt:EBITDA was 4.7-4.8x as at 31 December 2025, well within the requirement of less than 5.25x, and the Company's liquidity (undrawn committed facilities and cash) was £385m.

 

Overall trading since the start of 2026 is in line with the Company's expectations and momentum continues to build. While the consequences of the military action in Iran remain uncertain, Synthomer is passing through the significant increases in underlying raw materials and energy costs since the start of the conflict via pricing adjustments, while sales volumes in several product areas are increasing, benefitting from our regional manufacturing footprint. The Company's joint venture manufacturing operation and sales office in the Middle East are both currently operating as usual, and our global supply chains have remained robust to-date although we are monitoring the situation closely.

 

The Company continues to focus on delivering further year-on-year progress in 2026 driven primarily by its self-help actions.

 

Update on refinancing discussions

 

As previously announced, the Company remains actively engaged with its lenders with the objective of amending the key covenants and extending the maturity of its revolving credit and UK Export Finance debt facilities, which are due in H2 2027. These discussions are proceeding constructively, alongside our ongoing focus on delivering the broadened divestment programme. While the Company continues to explore options to support further leverage reduction and underpin the sustained delivery of the speciality chemicals strategy, the Board does not currently intend to issue new equity and is focused on concluding the debt refinancing process alongside the divestment programme. Kuala Lumpur Kepong Berhad Group ('KLK'), Synthomer's largest shareholder, remains very supportive of Synthomer's strategy and operational delivery.

 

Given the debt refinancing process above, the Company will publish its 2025 results in late April 2026.

 

 

Further information:

Investors: Faisal Tabbah, Vice President Investor Relations

Tel: +44 (0) 1279 775 306

Media: Nick Hasell, FTI Consulting

Tel: +44 (0) 203 727 1340

 

Notes

Synthomer plc is a leading supplier of high-performance, highly specialised polymers and ingredients that play vital roles in key sectors such as coatings, construction, adhesives, and health and protection - growing markets for customers who serve billions of end users worldwide. Headquartered in London, UK and listed there since 1971, we employ c.3,800 employees across our five innovation centres of excellence and 29 manufacturing sites across Europe, North America, Middle East and Asia. With more than 6,000 blue-chip customers and £1.7bn in continuing revenue in 2025, our business is built around three divisions, serving customers in attractive end markets where demand is driven by global megatrends including urbanisation, demographic change, climate change and sustainability, and shifting economic power. In Coatings & Construction Solutions, our specialist polymers enhance the sustainability and performance of a wide range of coatings and construction products. We serve customers in applications including architectural and masonry coatings, mortar modification, waterproofing and flooring, fibre bonding, and energy solutions. In Adhesive Solutions our products help our customers bond, modify and compatibilise surfaces and components for applications including tapes and labels, packaging, hygiene, tyres and plastic modification, improving permeability, strength, elasticity, damping, dispersion and grip. In Health & Protection and Performance Materials we are a world-leading supplier of water-based polymers for medical gloves, and a major European manufacturer of high-performance binders, foams and other products serving customers in a range of end markets. Our purpose is creating innovative and sustainable solutions for the benefit of customers and society. Around 20% of our sales volumes are from new and patent protected products. At our innovation centres of excellence in the UK, China, Germany, Malaysia and Ohio, USA we collaborate closely with our customers to develop new products and enhance existing ones tailored to their needs, with an increasing range of sustainability benefits. Our 2030 decarbonisation targets have been approved by the Science Based Targets initiative as being in line with what the latest climate science says is necessary to meet the goals of the Paris Agreement, and since 2021 we have held the London Stock Exchange Green Economy Mark, which recognises green technology businesses making a significant contribution to a more sustainable, low-carbon economy. Find us at www.synthomer.com or search for Synthomer on LinkedIn. Legal Entity Identifier (LEI): 213800EHT3TI1KPQQJ56.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSFSESAEMSEFD
Date   Source Headline
30th Jul 201912:54 pmRNSDirector/PDMR Shareholding
30th Jul 201912:53 pmRNSDirector/PDMR Shareholding
30th Jul 201912:52 pmRNSDirector/PDMR Shareholding
30th Jul 201912:51 pmRNSDirector/PDMR Shareholding
30th Jul 201912:50 pmRNSDirector/PDMR Shareholding
30th Jul 201912:48 pmRNSDirector/PDMR Shareholding
30th Jul 201912:48 pmRNSDirector/PDMR Shareholding
30th Jul 201911:31 amRNSResults of Rump Placing
30th Jul 20197:00 amRNSResults of Rights Issue
26th Jul 20192:48 pmRNSDirector/PDMR Shareholding
26th Jul 20192:46 pmRNSDirector/PDMR Shareholding
24th Jul 20194:34 pmRNSDirector Declaration
15th Jul 20197:00 amRNSAdmission of Nil Paid Rights
10th Jul 20191:49 pmRNSPublication of Circular and Prospectus
10th Jul 20191:34 pmRNSDirector/PDMR Shareholding
3rd Jul 20197:00 amRNSAcquisition
2nd Jul 20193:56 pmRNSDirector Declaration
13th Jun 201911:18 amRNSDirector Declaration
25th Apr 20194:45 pmRNSResult of AGM
25th Apr 20197:00 amRNSQ1 Trading Update
10th Apr 20194:51 pmRNSDirector/PDMR Shareholding
10th Apr 20194:50 pmRNSDirector/PDMR Shareholding
10th Apr 20194:43 pmRNSDirector/PDMR Shareholding
10th Apr 20194:41 pmRNSDirector/PDMR Shareholding
28th Mar 20193:51 pmRNSDirector/PDMR Shareholding
28th Mar 20193:50 pmRNSDirector/PDMR Shareholding
25th Mar 20193:15 pmRNSAnnual Financial Report
21st Mar 20193:39 pmRNSDirector Declaration
18th Mar 201910:02 amRNSDirector/PDMR Shareholding
12th Mar 201911:25 amRNSDirector/PDMR Shareholding
12th Mar 201911:23 amRNSDirector/PDMR Shareholding
5th Mar 20194:09 pmRNSDirector/PDMR Shareholding
4th Mar 20197:00 amRNSResults for the year ended 31 December 2018
1st Mar 20193:26 pmRNSDirector Declaration
3rd Dec 201810:54 amRNSHolding(s) in Company
9th Nov 201811:36 amRNSDirector/PDMR Shareholding
6th Nov 20187:00 amRNSQ3 Trading update
17th Oct 20189:29 amRNSDirector Declaration
21st Sep 20189:17 amRNSDirectorate Change
6th Aug 20187:00 amRNSResults for the six months ended 30 June 2018
11th Jul 20186:25 pmRNSDirector/PDMR Shareholding
10th Jul 20189:47 amRNSHolding(s) in Company
4th Jul 201811:45 amRNSHolding(s) in Company
4th Jul 201811:44 amRNSHolding(s) in Company
4th Jul 201811:43 amRNSHolding(s) in Company
28th Jun 20183:12 pmRNSUpdate on Proposed Offering
25th Jun 20187:19 amRNSPROPOSED OFFERING OF EUR300M BOND & REFINANCING
21st Jun 201810:16 amRNSResult of Extraordinary General Meeting
8th Jun 20187:00 amRNSEuropean Commission investigation
4th Jun 20181:02 pmRNSNotice of GM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.